first glp-1 FDA Approves Generic Liraglutide for Weight Loss The GLP-1 journey: from discovery

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

LFMD continues to trade in the price channel, but the daily relative strength index (RSI) is falling back down off the 60-band

The question of alcohol with tirzepatide mirrors the semaglutide conversation, as both medications affect how the body processes alcohol

What does this mean for Medicare coverage of anti-obesity drugs

T2D, non-alcoholic fatty liver disease (also known as metabolic dysfunction-associated steatotic liver disease) and hypertension diagnoses were all associated with lower weight loss efficacy, consistent with previous reports 22,23,24